Small molecule CYP34A inhibitor oncology therapeutics are being developed in collaboration between scientists at UC Irvine and U of Minnesota. These molecules have been shown effective against ER+ xenograft models of breast cancer. Due to their mechanism of action, these molecules may enhance treatment with tamoxifen and paclitaxel to decrease risk of recurrence.
We are currently looking for commercial partners to further develop these inhibitors for treatment of breast cancer, type II diabetes, or obesity.
|United States Of America||Issued Patent||10,272,055||04/30/2019||2015-143|
Additional Patent Pending